http://www.fiercebiotech.com/story/whos-next-big-pharmas-biotech-shopping-list/2012-07-16?utm_medium=nl&utm_source=internal bye bye, suckers.
It'd take a lot of $$$$$.... Potential buyers? The business news service speculates that Astellas, its partner, could make the numbers work. And so could AbbVie, the new pharma spinout coming from Abbott Labs ($ABT), which has been wheeling and dealing in the months ahead of the corporate split. A spokesperson for Medivation, which is helmed by David Hung, says that the best way to maximize shareholder value is to remain a standalone company. That said, the CEO is a consummate dealmaker. Read more: Who's next on Big Pharma's biotech shopping list? - FierceBiotech http://www.fiercebiotech.com/story/whos-next-big-pharmas-biotech-shopping-list/2012-07-16?utm_medium=nl&utm_source=internal#ixzz216s3euVq
